RIV Capital Competitors

RIV Capital (TSE:RIV) and Willow Biosciences Inc. (WLLW.TO) (TSE:WLLW) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, profitability, dividends, earnings and risk.

Profitability

This table compares RIV Capital and Willow Biosciences Inc. (WLLW.TO)'s net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for RIV Capital and Willow Biosciences Inc. (WLLW.TO), as provided by MarketBeat.com.

RIV Capital currently has a consensus target price of C$4.00, indicating a potential upside of 90.48%. Willow Biosciences Inc. (WLLW.TO) has a consensus target price of C$2.25, indicating a potential upside of 74.42%. Given RIV Capital's higher probable upside, equities analysts clearly believe RIV Capital is more favorable than Willow Biosciences Inc. (WLLW.TO).

Valuation and Earnings

This table compares RIV Capital and Willow Biosciences Inc. (WLLW.TO)'s top-line revenue, earnings per share and valuation.

Willow Biosciences Inc. (WLLW.TO) has lower revenue, but higher earnings than RIV Capital. Willow Biosciences Inc. (WLLW.TO) is trading at a lower price-to-earnings ratio than RIV Capital, indicating that it is currently the more affordable of the two stocks.

RIV Capital (TSE:RIV) and MediPharm Labs (TSE:LABS) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, earnings, risk, analyst recommendations, institutional ownership and dividends.

Valuation and Earnings

This table compares RIV Capital and MediPharm Labs' revenue, earnings per share and valuation.

RIV Capital has higher earnings, but lower revenue than MediPharm Labs. RIV Capital is trading at a lower price-to-earnings ratio than MediPharm Labs, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares RIV Capital and MediPharm Labs' net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of current ratings and price targets for RIV Capital and MediPharm Labs, as reported by MarketBeat.com.

RIV Capital currently has a consensus price target of C$4.00, indicating a potential upside of 90.48%. MediPharm Labs has a consensus price target of C$1.53, indicating a potential upside of 218.75%. Given MediPharm Labs' stronger consensus rating and higher possible upside, analysts plainly believe MediPharm Labs is more favorable than RIV Capital.

Summary

MediPharm Labs beats RIV Capital on 6 of the 8 factors compared between the two stocks.

RIV Capital (TSE:RIV) and Khiron Life Sciences (CVE:KHRN) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, valuation, risk and earnings.

Analyst Ratings

This is a breakdown of current ratings and target prices for RIV Capital and Khiron Life Sciences, as reported by MarketBeat.com.

RIV Capital currently has a consensus target price of C$4.00, suggesting a potential upside of 90.48%. Khiron Life Sciences has a consensus target price of C$1.20, suggesting a potential upside of 122.22%. Given Khiron Life Sciences' higher probable upside, analysts plainly believe Khiron Life Sciences is more favorable than RIV Capital.

Earnings & Valuation

This table compares RIV Capital and Khiron Life Sciences' gross revenue, earnings per share (EPS) and valuation.

Khiron Life Sciences has lower revenue, but higher earnings than RIV Capital. RIV Capital is trading at a lower price-to-earnings ratio than Khiron Life Sciences, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares RIV Capital and Khiron Life Sciences' net margins, return on equity and return on assets.

Summary

Khiron Life Sciences beats RIV Capital on 4 of the 6 factors compared between the two stocks.

Delta 9 Cannabis (TSE:DN) and RIV Capital (TSE:RIV) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, institutional ownership, earnings, profitability, dividends, valuation and analyst recommendations.

Profitability

This table compares Delta 9 Cannabis and RIV Capital's net margins, return on equity and return on assets.

Earnings and Valuation

This table compares Delta 9 Cannabis and RIV Capital's top-line revenue, earnings per share (EPS) and valuation.

Delta 9 Cannabis has higher revenue and earnings than RIV Capital. Delta 9 Cannabis is trading at a lower price-to-earnings ratio than RIV Capital, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current recommendations and price targets for Delta 9 Cannabis and RIV Capital, as reported by MarketBeat.com.

Delta 9 Cannabis presently has a consensus target price of C$1.24, suggesting a potential upside of 113.79%. RIV Capital has a consensus target price of C$4.00, suggesting a potential upside of 90.48%. Given Delta 9 Cannabis' stronger consensus rating and higher probable upside, equities research analysts clearly believe Delta 9 Cannabis is more favorable than RIV Capital.

Summary

Delta 9 Cannabis beats RIV Capital on 6 of the 8 factors compared between the two stocks.

Meta Growth (CVE:META) and RIV Capital (TSE:RIV) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, earnings, institutional ownership and profitability.

Earnings and Valuation

This table compares Meta Growth and RIV Capital's gross revenue, earnings per share (EPS) and valuation.

Meta Growth has higher revenue and earnings than RIV Capital. RIV Capital is trading at a lower price-to-earnings ratio than Meta Growth, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Meta Growth and RIV Capital's net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of recent ratings for Meta Growth and RIV Capital, as provided by MarketBeat.com.

RIV Capital has a consensus price target of C$4.00, indicating a potential upside of 90.48%. Given RIV Capital's higher possible upside, analysts clearly believe RIV Capital is more favorable than Meta Growth.

Summary

Meta Growth beats RIV Capital on 4 of the 6 factors compared between the two stocks.

48North Cannabis (CVE:NRTH) and RIV Capital (TSE:RIV) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, dividends, institutional ownership, profitability, earnings, analyst recommendations and risk.

Analyst Recommendations

This is a summary of recent recommendations for 48North Cannabis and RIV Capital, as provided by MarketBeat.

RIV Capital has a consensus price target of C$4.00, indicating a potential upside of 90.48%. Given RIV Capital's higher probable upside, analysts plainly believe RIV Capital is more favorable than 48North Cannabis.

Earnings and Valuation

This table compares 48North Cannabis and RIV Capital's top-line revenue, earnings per share and valuation.

48North Cannabis has higher revenue and earnings than RIV Capital. RIV Capital is trading at a lower price-to-earnings ratio than 48North Cannabis, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares 48North Cannabis and RIV Capital's net margins, return on equity and return on assets.

Summary

48North Cannabis beats RIV Capital on 4 of the 6 factors compared between the two stocks.